Added to YB: 2026-01-06
Pitch date: 2026-01-03
IVVD [bullish]
Invivyd, Inc.
-5.18%
current return
Author Info
JNap is Head of Research for Remsen Investors LP, a long/short biopharma fund and owner of Bio5C, an independent biopharma research service. Sign up for the newsletter.
Company Info
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
Market Cap
$582.8M
Pitch Price
$2.51
Price Target
N/A
Dividend
N/A
EV/EBITDA
-8.49
P/E
-5.54
EV/Sales
10.00
Sector
Biotechnology
Category
growth
Six Lottos For 2026 - Invivyd, Inc.
IVVD (lotto play): COVID remains high-risk w/ <50% vaccine efficacy, 25% uptake. Only approved non-mRNA alternative Pemgarda limited by IV infusion. VYD-2311 3rd-gen candidate enables IM injection, 6-mo dosing. Phase 3 trials Declaration & Liberty enrolling, data Q2 2026. $750M mcap vs multi-billion booster market potential - 10% of 60M Americans = $3B sales. Cidara 2.0 opportunity.
Read full article (2 min)